{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:47:39Z","timestamp":1790059659394,"version":"4.0.1"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"77","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,10,2]]},"DOI":"10.18632\/oncotarget.26015","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T15:10:33Z","timestamp":1538493033000},"page":"34628-34638","source":"Crossref","is-referenced-by-count":73,"title":["The clinical relevance of progestogens in hormonal contraception: Present status and future developments"],"prefix":"10.18632","volume":"9","author":[{"given":"Pedro-Antonio","family":"Regidor","sequence":"first","affiliation":[{"name":"Exeltis Europe & Germany, 85737 Ismaning, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,10,2]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","article-title":"Classification and pharmacology of progestins","volume":"61","author":"Thijssen","year":"2008","journal-title":"Maturitas"},{"key":"2","first-page":"41","article-title":"Non-contraceptive benefits of oral hormonal contraceptives","volume":"11","author":"Schindler","year":"2013","journal-title":"Int J Endocrinol Metab"},{"key":"3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2010.05.005","article-title":"Non-contraceptive health benefits of intrauterine hormonal systems","volume":"82","author":"Fraser","year":"2010","journal-title":"Contraception"},{"key":"4","doi-asserted-by":"crossref","DOI":"10.2307\/2137913","volume-title":"Contraceptive Technology: Seventeenth Revised Edition, Irvington Publishers, New York, 1998","author":"Hatcher","year":"1994"},{"key":"5","volume-title":"The Best Intentions: Unintended Pregnancy and the Well- Being of Children and Families","author":"Eisenberg","year":"1994"},{"key":"6","unstructured":"PRAC referral assessment report. Procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data. Combined hormonal contraceptives containing medicinal products INN: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate. Procedure number: EMEA\/H\/A-31\/1356. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Combined_hormonal_contraceptives\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500160272.pdf."},{"key":"7","unstructured":"Opinion of the Committee for Medicinal Products for Human Use pursuant to Article 31 of Directive 2001\/83\/ EC for dienogest\/ethinylestradiol containing medicinal products indicated in acne. EMA\/CHMP\/562861\/2016. Committee for Medicinal Products for Human Usehttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Dienogest_Ethinylestradiol_containing_medicinal_products_indicated_in_acne\/human_referral_000398.jsp&mid=WC0b01ac05805c516f."},{"key":"8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0039-128X(92)90016-3","article-title":"Steroid research at Syntex: \u201cthe pill\u201d and cortisone","volume":"57","author":"Djerassi","year":"1992","journal-title":"Steroids"},{"key":"9","first-page":"157","article-title":"Pharmacology of progestogens","volume":"8","author":"Kuhl","year":"2011","journal-title":"J Reproduktionsmed Endokrinol"},{"key":"10","unstructured":"Wiechert, Bittler, Krebs, Casals-Stenzel, Losert. Deutsches Patent Nr. 2652761 (Priorit\u00e4t: 1976)."},{"key":"11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0378-5122(94)00882-8","article-title":"Influence of route of administration on progesterone metabolism","volume":"21","author":"Backstrom","year":"1995","journal-title":"Maturitas"},{"key":"12","first-page":"502","article-title":"Physiological action of progesterone in target tissues","volume":"18","author":"Clarke","year":"1997","journal-title":"Endocr Rev"},{"key":"13","first-page":"395","volume-title":"IUPAC","author":"Robin Ganellin","year":"2006"},{"key":"14","doi-asserted-by":"publisher","first-page":"83334","DOI":"10.18632\/oncotarget.19833","article-title":"Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone","volume":"8","author":"Schindler","year":"2017","journal-title":"Oncotarget"},{"key":"15","first-page":"168","article-title":"Hormonimplantate zur Kontrazeption bei der Frau","volume":"10","author":"Mueck","year":"2013","journal-title":"J Reproduktionsmed Endokrinol"},{"key":"16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.contraception.2006.01.006","article-title":"Oral contraceptive use and risk of fractures","volume":"73","author":"Mosekilde","year":"2006","journal-title":"Contraception"},{"key":"17","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1210\/jc.2010-0032","article-title":"Use of depot medroxyprogesterone acetate and fracture risk","volume":"95","author":"Meier","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.contraception.2012.04.009","article-title":"Hormonal contraception and bone metabolism: a systematic review","volume":"86","author":"Di Carlo","year":"2012","journal-title":"Contraception"},{"key":"19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11154-011-9180-6","article-title":"Update on hormonal contraception and bone density","volume":"12","author":"Kaunitz","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/09513590701584931","article-title":"Long-term effects of progestins on bone quality and fractures","volume":"23","author":"Thijssen","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"21","first-page":"1265","article-title":"Contemporary Hormonal Contraception and the Risk of Breast Cancer","volume":"378","author":"Keefe","year":"2018","journal-title":"N Engl J Med"},{"key":"22","first-page":"16","article-title":"Aktuelles: intrauterine hormonelle Kontrazeption","volume":"4","author":"R\u00f6mer","year":"2012","journal-title":"J Gynakol Endokrinol"},{"key":"23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/jfprhc-2014-100980","article-title":"Jaydess\u00ae levonorgestrel intrauterine system","volume":"40","author":"Craik","year":"2014","journal-title":"J Fam Plann Reprod Health Care"},{"key":"24","unstructured":"WHO Medical eligibility criteria for contraceptive use, 5th ed. 2015. http:\/\/www.who.int\/reproductivehealth\/publications\/family_planning\/MEC-5\/en\/."},{"key":"25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/humrep\/14.4.982","article-title":"A comparison of the inhibition of ovulation achieved by desogestrel 75 mg and levonorgestrel 30 mg daily","volume":"14","author":"Bennink","year":"1999","journal-title":"Hum Reprod"},{"key":"26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jbspin.2008.09.014","article-title":"Impact of combined and progestogen-only contraceptives on bone mineral density","volume":"76","author":"de Vernejoul","year":"2009","journal-title":"Joint Bone Spine"},{"key":"27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/oxfordjournals.humrep.a019245","article-title":"Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses","volume":"11","author":"Coelingh Bennink","year":"1996","journal-title":"Hum Reprod"},{"key":"28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/978-1-4614-6579-9","volume-title":"Contraception for Adolescent and Young Adult Women","author":"Gilliam","year":"2014"},{"key":"29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3109\/09513590.2014.950648","article-title":"Mechanisms of action of oral emergency contraception","volume":"30","author":"Lalitkumar","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.contraception.2010.05.015","article-title":"Hormonal evaluation and midcycle detection of intrauterine glycodelin in women treated with levonorgestrel as in emergency contraception","volume":"82","author":"Larrea","year":"2010","journal-title":"Contraception"},{"key":"31","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1093\/humrep\/deq157","article-title":"Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture","volume":"25","author":"Croxatto","year":"2010","journal-title":"Hum Reprod"},{"key":"32","unstructured":"European Medicines Agency. Levonorgestrel and ulipristal remain suitable emergercy contraceptives for all women, regardless of bodyweight. 2014. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/07\/news_detail_002145.jsp&mid=WC0b01ac058004d5c1."},{"key":"33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(10)60101-8","article-title":"Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis","volume":"375","author":"Gainer","year":"2010","journal-title":"Lancet"},{"key":"34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/13625187.2017.1413179","article-title":"Pharmacokinetic bioequivalence, safety and acceptability of Ornibel\u00ae, a new polymer composition contraceptive vaginal ring (etonogestrel\/ethinylestradiol 11.00\/3.474\u2005mg) compared with Nuvaring\u00ae (etonogestrel\/ethinylestradiol 11.7\/2.7\u2005mg)","volume":"22","author":"Ronchi","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","article-title":"Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability","volume":"92","author":"Drouin","year":"2015","journal-title":"Contraception"},{"key":"36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.contraception.2015.12.007","article-title":"Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake","volume":"93","author":"Skouby","year":"2016","journal-title":"Contraception"},{"key":"37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3109\/09513590.2016.1161743","article-title":"Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4\u2005mg formulation in a 24\u2005+\u20054 cycle with desogestrel 75\u2005\u03bcg per day","volume":"32","author":"Schindler","year":"2016","journal-title":"Gynecol Endocrinol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T19:36:04Z","timestamp":1589052964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,2]]},"references-count":37,"journal-issue":{"issue":"77","published-print":{"date-parts":[[2018,10,2]]}},"alternative-id":["26015","30349654"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26015","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,2]]}}}